Treatment of Attention Deficit Hyperactivity Disorder (ADHD)

First-Line Treatment

The American Academy of Pediatrics recommends stimulants as first-line therapy, with methylphenidate being the preferred initial option for improving focus in patients with ADHD 1
Different extended-release formulations of methylphenidate allow for individualized treatment to provide symptomatic coverage throughout the day 1
The efficacy of methylphenidate is well-established for improving focus and attention in ADHD patients, with once-daily dosing preferred to increase treatment adherence 1
Lisdexanfetamine is approved as a first-line treatment in the United States, but as a second-line treatment in many European countries, and should be the preferred option when methylphenidate is not beneficial after appropriate treatment (dose and duration) 1

Lisdexanfetamine is preferred over non-stimulants when methylphenidate fails, due to its efficacy and safety profile 1

Methylphenidate offers the best efficiency due to its approval, established safety profile, multiple available formulations, and recommendation as a first-line treatment in guidelines 1
The concept of "efficiency" refers to the best risk-benefit ratio and clinical applicability, not necessarily the strongest effect, as noted by the American Academy of Pediatrics 1

Modafinil is approved for excessive daytime sleepiness in narcolepsy, obstructive sleep apnea (with CPAP), and shift work sleep disorder, but not for ADHD, as stated by the FDA 2
Modafinil has shown significant improvement in memory and attention in randomized trials for cognitive function and focus in cancer survivors, but this is a different clinical context from ADHD 3